Home/Filings/4/0002003059-25-000004
4//SEC Filing

Smith Robert Paul JR 4

Accession 0002003059-25-000004

CIK 0001728117other

Filed

Oct 1, 8:00 PM ET

Accepted

Oct 2, 4:13 PM ET

Size

5.6 KB

Accession

0002003059-25-000004

Insider Transaction Report

Form 4
Period: 2025-10-01
Smith Robert Paul JR
Chief Commercial Officer
Transactions
  • Award

    Common Stock

    2025-10-01+162,500162,500 total
Holdings
  • Common Stock

    (indirect: By Trust)
    25,000
Footnotes (1)
  • [F1]Represents performance stock unit award, which will vest in full upon the earlier of (i) the approval of a new drug application for seralutinib or (ii) a change in control, in either case on or prior to the fourth anniversary of the grant date, and subject to the Reporting Person's continuous service to the Issuer.

Issuer

Gossamer Bio, Inc.

CIK 0001728117

Entity typeother

Related Parties

1
  • filerCIK 0002003059

Filing Metadata

Form type
4
Filed
Oct 1, 8:00 PM ET
Accepted
Oct 2, 4:13 PM ET
Size
5.6 KB